Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: Implications for interrupting vertical transmission

J. B. Jackson

Research output: Contribution to journalArticle

Abstract

Use of zidovudine (AZT) in pregnant women has recently been reported to reduce the rate of vertical transmission of human immunodeficiency virus type 1 (HIV-1) possibly through a reduction in maternal viral load. To determine how quickly AZT is able to reduce viral load, infectious virus and plasma HIV-1 RNA were sequentially measured in an HIV-1-infected patient at short intervals (hours) after initiation of oral AZT. Peripheral blood samples were collected at baseline, 1, 2, 4, 8, 12, 24, 48 hours, and 1 week after initiation of AZT therapy (500 mg/day) for quantitative plasma HIV-1 RNA levels, p24 antigen levels, and AZT levels. Quantitative HIV-1 peripheral blood mononuclear cell and plasma cultures, CD4 cell counts, and MT-2 cell assays for syncytium-inducing phenotype were performed at baseline, 1, 2 days, and 1 week after initiation of AZT therapy. A significant drop in viral load did not occur until after 24-48 hours. AZT should probably be administered at least 2 days prior to anticipated delivery, if a reduced maternal viral load is responsible for AZT's efficacy in preventing vertical transmission.

Original languageEnglish (US)
Pages (from-to)358-361
Number of pages4
JournalPediatric AIDS and HIV Infection
Volume6
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

Zidovudine
Viral Load
HIV-1
Mothers
RNA
Therapeutics
Giant Cells
CD4 Lymphocyte Count
Pregnant Women
Blood Cells
Cell Culture Techniques
Viruses
Phenotype
Antigens

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Acute decrease in HIV-1 viral load after initiation of zidovudine therapy : Implications for interrupting vertical transmission. / Jackson, J. B.

In: Pediatric AIDS and HIV Infection, Vol. 6, No. 6, 1995, p. 358-361.

Research output: Contribution to journalArticle

@article{71d7dd99560f4dcca9f572d2a328428c,
title = "Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: Implications for interrupting vertical transmission",
abstract = "Use of zidovudine (AZT) in pregnant women has recently been reported to reduce the rate of vertical transmission of human immunodeficiency virus type 1 (HIV-1) possibly through a reduction in maternal viral load. To determine how quickly AZT is able to reduce viral load, infectious virus and plasma HIV-1 RNA were sequentially measured in an HIV-1-infected patient at short intervals (hours) after initiation of oral AZT. Peripheral blood samples were collected at baseline, 1, 2, 4, 8, 12, 24, 48 hours, and 1 week after initiation of AZT therapy (500 mg/day) for quantitative plasma HIV-1 RNA levels, p24 antigen levels, and AZT levels. Quantitative HIV-1 peripheral blood mononuclear cell and plasma cultures, CD4 cell counts, and MT-2 cell assays for syncytium-inducing phenotype were performed at baseline, 1, 2 days, and 1 week after initiation of AZT therapy. A significant drop in viral load did not occur until after 24-48 hours. AZT should probably be administered at least 2 days prior to anticipated delivery, if a reduced maternal viral load is responsible for AZT's efficacy in preventing vertical transmission.",
author = "Jackson, {J. B.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "358--361",
journal = "Pediatric AIDS and HIV Infection",
issn = "1045-5418",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Acute decrease in HIV-1 viral load after initiation of zidovudine therapy

T2 - Implications for interrupting vertical transmission

AU - Jackson, J. B.

PY - 1995

Y1 - 1995

N2 - Use of zidovudine (AZT) in pregnant women has recently been reported to reduce the rate of vertical transmission of human immunodeficiency virus type 1 (HIV-1) possibly through a reduction in maternal viral load. To determine how quickly AZT is able to reduce viral load, infectious virus and plasma HIV-1 RNA were sequentially measured in an HIV-1-infected patient at short intervals (hours) after initiation of oral AZT. Peripheral blood samples were collected at baseline, 1, 2, 4, 8, 12, 24, 48 hours, and 1 week after initiation of AZT therapy (500 mg/day) for quantitative plasma HIV-1 RNA levels, p24 antigen levels, and AZT levels. Quantitative HIV-1 peripheral blood mononuclear cell and plasma cultures, CD4 cell counts, and MT-2 cell assays for syncytium-inducing phenotype were performed at baseline, 1, 2 days, and 1 week after initiation of AZT therapy. A significant drop in viral load did not occur until after 24-48 hours. AZT should probably be administered at least 2 days prior to anticipated delivery, if a reduced maternal viral load is responsible for AZT's efficacy in preventing vertical transmission.

AB - Use of zidovudine (AZT) in pregnant women has recently been reported to reduce the rate of vertical transmission of human immunodeficiency virus type 1 (HIV-1) possibly through a reduction in maternal viral load. To determine how quickly AZT is able to reduce viral load, infectious virus and plasma HIV-1 RNA were sequentially measured in an HIV-1-infected patient at short intervals (hours) after initiation of oral AZT. Peripheral blood samples were collected at baseline, 1, 2, 4, 8, 12, 24, 48 hours, and 1 week after initiation of AZT therapy (500 mg/day) for quantitative plasma HIV-1 RNA levels, p24 antigen levels, and AZT levels. Quantitative HIV-1 peripheral blood mononuclear cell and plasma cultures, CD4 cell counts, and MT-2 cell assays for syncytium-inducing phenotype were performed at baseline, 1, 2 days, and 1 week after initiation of AZT therapy. A significant drop in viral load did not occur until after 24-48 hours. AZT should probably be administered at least 2 days prior to anticipated delivery, if a reduced maternal viral load is responsible for AZT's efficacy in preventing vertical transmission.

UR - http://www.scopus.com/inward/record.url?scp=0029564973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029564973&partnerID=8YFLogxK

M3 - Article

C2 - 11361462

AN - SCOPUS:0029564973

VL - 6

SP - 358

EP - 361

JO - Pediatric AIDS and HIV Infection

JF - Pediatric AIDS and HIV Infection

SN - 1045-5418

IS - 6

ER -